Tuesday, June 01, 2010 8:54:39 AM
Investor Clueso Subsribers,
InvestorClueso is pleased to alert our subscribers to Herborium Group, Inc. (HBRM) which is poised to become a leading company in the Natural Healthcare Alternative market.
Herborium Group, Inc. (www.herborium.com
), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com
), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
It is expected that in 2010, 65% of doctors in the US will recommend herbal or alternative medicinal products and 67% of the US population will use natural medications or alternative therapies. Big Pharma currently lacks a pipeline in this sector.
AcnEase? is one of many products that Herborium sells globally to high growth niches in the $250 billion dollar natural and alternative health sector.
The company has been diligently setting up distribution networks in order to tap the $50 billion world-wide market for acne medication as well.
Herborium, Inc.?s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company?s projections are for $20 million in sales with a similar high gross profit margin.
Herborium Group, Inc., (HBRM) is a novel botanical therapeutics? company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billion in the USA and UK alone.
This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies, Herborium introduces its own botanical therapeutics? defined as ?bridge products?, an emerging category of natural medicines whose safety and efficacy are validated through clinical studies.
Herborium offers a robust business model designed to capitalize on the changing landscape in the healthcare sector spearheaded by novel regulatory, market and technological trends, and the cost advantage of natural medicinal products. Herborium?s unique blend of management?s expertise, clinical and regulatory know how in the US, Europe and PRC, diversified proprietary Botanical Therapeutics? portfolio and innovative marketing strategies provide for high-value, high-return opportunity and a strong entry barrier for potential competitors.
Herborium strives to become the Leader in developing and marketing novel, safe and effective, proprietary botanical therapeutics? (botanical based medicines), and innovative support content which target selected, unmet medical needs for disease treatment, management, and prevention.
The Company?s business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products into Western markets.
?Technology Ownership (IP)
?Exclusive Distribution Rights